A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Plasmodium falciparum merozoite surface protein 3 is a malaria vaccine candidate that was identified, characterised, and developed based on a unique immuno-clinical approach. The vaccine construct was derived from regions fully conserved among various strains and containing B cell epitopes targeted...
Main Authors: | Pierre Druilhe, François Spertini, Daw Soesoe, Giampietro Corradin, Pedro Mejia, Subhash Singh, Regine Audran, Ahmed Bouzidi, Claude Oeuvray, Christian Roussilhon |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2005-11-01
|
Series: | PLoS Medicine |
Online Access: | http://europepmc.org/articles/PMC1277929?pdf=render |
Similar Items
-
A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Published: (2005-11-01) -
The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.
by: Régine Audran, et al.
Published: (2009-10-01) -
Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium
by: F Mutapi, et al.
Published: (2007-06-01) -
Understanding human-Plasmodium falciparum immune interactions uncovers the immunological role of worms.
by: Christian Roussilhon, et al.
Published: (2010-01-01) -
Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development.
by: Caroline Kulangara, et al.
Published: (2009-05-01)